Portal de Periódicos da CAPES

EGFR and Ki-67 expression in oral squamous cell carcinoma using tissue microarray technology

2010; Wiley; Linguagem: Inglês

10.1111/j.1600-0714.2009.00876.x

1600-0714

Luı́s Monteiro, Márcio Diniz Freitas, Tomás García‐Caballero, Jerónimo Forteza, Máximo Fraga,

Advanced Biosensing Techniques and Applications

Journal of Oral Pathology & MedicineVolume 39, Issue 7 p. 571-578 EGFR and Ki-67 expression in oral squamous cell carcinoma using tissue microarray technology Luís Silva Monteiro, Luís Silva Monteiro Department of Oral Surgery and Oral Medicine, Higher Institute of Health Sciences, Paredes, Portugal and Dental Sciences Group – Health Sciences Investigation Center (CICS), Paredes, PortugalSearch for more papers by this authorMárcio Diniz-Freitas, Márcio Diniz-Freitas Departments of Oral Surgery and Oral Medicine, School of Dentistry, University of Santiago de Compostela, SpainSearch for more papers by this authorTomás Garcia-Caballero, Tomás Garcia-Caballero Department of Morphological Sciences, School of Medicine-University Clinical Hospital, University of Santiago de Compostela, SpainSearch for more papers by this authorJerónimo Forteza, Jerónimo Forteza Department of Pathology and Forensic Sciences, School of Medicine-University Clinical Hospital, University of Santiago de Compostela, SpainSearch for more papers by this authorMáximo Fraga, Máximo Fraga Department of Pathology and Forensic Sciences, School of Medicine-University Clinical Hospital, University of Santiago de Compostela, SpainSearch for more papers by this author Luís Silva Monteiro, Luís Silva Monteiro Department of Oral Surgery and Oral Medicine, Higher Institute of Health Sciences, Paredes, Portugal and Dental Sciences Group – Health Sciences Investigation Center (CICS), Paredes, PortugalSearch for more papers by this authorMárcio Diniz-Freitas, Márcio Diniz-Freitas Departments of Oral Surgery and Oral Medicine, School of Dentistry, University of Santiago de Compostela, SpainSearch for more papers by this authorTomás Garcia-Caballero, Tomás Garcia-Caballero Department of Morphological Sciences, School of Medicine-University Clinical Hospital, University of Santiago de Compostela, SpainSearch for more papers by this authorJerónimo Forteza, Jerónimo Forteza Department of Pathology and Forensic Sciences, School of Medicine-University Clinical Hospital, University of Santiago de Compostela, SpainSearch for more papers by this authorMáximo Fraga, Máximo Fraga Department of Pathology and Forensic Sciences, School of Medicine-University Clinical Hospital, University of Santiago de Compostela, SpainSearch for more papers by this author First published: 01 August 2010 https://doi.org/10.1111/j.1600-0714.2009.00876.xCitations: 8 Luís Silva Monteiro, Centro de Investigação em Ciências da Saúde (CICS), Instituto Superior de Ciências da Saúde – Norte, Rua Central de Gandra, 1317, 4585-116 Gandra PRD, Portugal. Tel: +351919120226, E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract J Oral Pathol Med (2010) 39: 571–578 Objective: Our aim was to validate the use of tissue microarrays (TMA) in oral squamous cell carcinomas (OSCC) to analyse epidermal growth factor receptor (EGFR) and Ki-67 expression. We also analysed the relationship that the expression of these markers may have with clinical, pathological and survival variables. Patients and methods: The study sample comprised 39 unselected patients diagnosed and treated for OSCC. We analysed Ki-67 and EGFR expression by immunohistochemistry on formalin-fixed, paraffin-embedded surgical specimens. Whole sections (WS) were compared with double 1.5 mm core-tissue microarrays. Results: High EGFR expression was observed both on TMA (in 98% of the cases) and WS (in 100% of the cases) with substantial agreement kappa value (0.720). EGFR expression was not significantly associated with clinical, pathological and survival variables on TMA and WS. Ki-67 analysis showed a Spearman correlation of 0.741 with a Ki-67 mean labelling index of 45% in TMA and 56.8% in WS. We found a significant relationship between gender and Ki-67 labelling index on WS (P = 0.022) and TMA (P = 0.002). Clinical stage was the only parameter in multivariate analysis that had a significant predictive value. Conclusion: We demonstrate that dual 1.5 mm core TMA is a valid, rapid, economical and tissue-saving way to study OSCC biopsies and that it presents strong correlation with the WS. EGFR overexpression in OSCC suggests that these tumours may be a candidate for therapy investigation directed to EGFR. References 1 Stewart BW, Kleihues P. World cancer report. Geneva: International Agency for Research on Cancer, 2003; 232–6. Google Scholar 2 Moore SR, Pierce AM, Wilson DF. “Oral Cancer”– the terminology dilemma. Oral Dis 2000; 6: 191–3. 10.1111/j.1601-0825.2000.tb00332.x CASPubMedWeb of Science®Google Scholar 3 Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005; 103: 2435–46. 10.1002/cncr.21123 CASPubMedWeb of Science®Google Scholar 4 Hsu FD, Nielsen TO, Alkushi A, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 2002; 15: 1374–80. 10.1097/01.MP.0000039571.02827.CE PubMedWeb of Science®Google Scholar 5 Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarrays for high throughput molecular profiling of cancer. Hum Mol Genet 2001; 10: 657–62. 10.1093/hmg/10.7.657 CASPubMedWeb of Science®Google Scholar 6 Andersen CL, Monni O, Wagner U, et al. High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol 2002; 161: 73–9. 10.1016/S0002-9440(10)64158-2 CASPubMedWeb of Science®Google Scholar 7 Radhakrishnan R, Solomon M, Satyamoorthy K, Martin LE, Lingen MW. Tissue microarray – a high-throughput molecular analysis in head and neck cancer. J Oral Pathol Med 2008; 37: 166–76. 10.1111/j.1600-0714.2007.00606.x CASPubMedWeb of Science®Google Scholar 8 Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844–7. 10.1038/nm0798-844 CASPubMedWeb of Science®Google Scholar 9 Shergill IS, Shergill NK, Arya M, Patel HRH. Tissue microarrays: a current medical research tool. Curr Med Res Opin 2004; 20: 707–12. 10.1185/030079904125003412 CASPubMedWeb of Science®Google Scholar 10 Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003; 16: 79–85. 10.1097/01.MP.0000047307.96344.93 PubMedWeb of Science®Google Scholar 11 Watson NF, Madjd Z, Scrimegour D, et al. Evidence that p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J Surg Oncol 2005; 3: 47. 10.1186/1477-7819-3-47 PubMedGoogle Scholar 12 Gulmann C, Butler D, Kay E, Grace A, Leader M. Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology 2003; 42: 70–6. 10.1046/j.1365-2559.2003.01556.x CASPubMedWeb of Science®Google Scholar 13 Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000; 31: 406–14. 10.1053/hp.2000.7295 CASPubMedWeb of Science®Google Scholar 14 Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004; 17: 790–7. 10.1038/modpathol.3800120 CASPubMedWeb of Science®Google Scholar 15 Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001; 158: 1245–51. 10.1016/S0002-9440(10)64075-8 CASPubMedWeb of Science®Google Scholar 16 Rodríguez AL, Llena FV, Ángel RC, Trull JL, Mas AG. Validación histopatológica de la tecnología tissue-microarray de cáncer de urotelio. Nuestra experiencia. Actas Urol Esp 2004; 28: 215–20. Google Scholar 17 Chen B, Van Der Brekel MW, Buschers W, Balm AJ, Velthuysen ML. Validation of tissue array technology in head and neck squamous cell carcinoma. Head Neck 2003; 25: 922–30. 10.1002/hed.10308 CASPubMedWeb of Science®Google Scholar 18 Fons G, Hasibuan SM, Van Der Velden J, Ten Kate FJW. Validation of tissue microarray technology in endometrioid cancer of the endometrium. J Clin Pathol 2007; 60: 500–3. 10.1136/jcp.2006.040170 CASPubMedWeb of Science®Google Scholar 19 Fons G, Van Der Velden J, Burger M, Ten Kate F. Validation of tissue microarray technology in vulvar cancer. Int J Gynecol Pathol 2009; 28: 76–82. 10.1097/PGP.0b013e3181817b2a PubMedWeb of Science®Google Scholar 20 Boone J, Van Hillegersberg R, Van Diest PJ, Offerhaus GJ, Rinkes IH, Ten Kate F. Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Arch 2008; 452: 507–14. 10.1007/s00428-008-0602-0 CASPubMedWeb of Science®Google Scholar 21 American Joint Committee. American Joint Committee on Cancer: AJCC – Cancer Staging Handbook. Classification of malignant tumors, 6th edn. New York: Springer, 2002; 27–87. Google Scholar 22 Barnes L, Everson JW, Reichart P, Sidransky D. World health organization classification of tumours: pathology and genetics of head and neck tumours. Lyon, France: IARC Press, 2005. Google Scholar 23 Diniz-Freitas M, García-Caballero T, Antúnez-López J, Gándara-Rey JM, García-García A. Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis 2007; 13: 285–90. 10.1111/j.1601-0825.2006.01280.x CASPubMedWeb of Science®Google Scholar 24 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159–74. 10.2307/2529310 CASPubMedWeb of Science®Google Scholar 25 Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 1986; 55: 24–8. Google Scholar 26 Wan WH, Furtuna MB, Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 1987; 103: 121–9. 10.1016/0022-1759(87)90249-3 CASPubMedWeb of Science®Google Scholar 27 Yearsley MM, Hammond EH, Pajak TF, et al. Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol 2002; 15: 1366–77. Google Scholar 28 Griffin MC, Robinson RA, Trask DK. Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx. Mod Pathol 2003; 16: 1181–8. 10.1097/01.MP.0000097284.40421.D6 PubMedWeb of Science®Google Scholar 29 Nocito A, Bubendorf L, Tinner EM, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001; 194: 349–57. 10.1002/1096-9896(200107)194:3 3.0.CO;2-D CASPubMedWeb of Science®Google Scholar 30 Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943–9. 10.1038/labinvest.3780204 CASPubMedWeb of Science®Google Scholar 31 Gomaa W, Ke Y, Fujii H, Helliwell T. Tissue microarray of head and neck squamous carcinoma: validation of the methology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch 2005; 447: 701–9. 10.1007/s00428-005-0002-7 CASPubMedWeb of Science®Google Scholar 32 Ulanovski D, Stern Y, Roizman P, Shpitzer T, Popovtzer A, Feinmesser R. Expression of EGFR and Cerb-B2 as prognostic factors in cancer of the tongue. Oral Oncol 2004; 40: 532–7. 10.1016/j.oraloncology.2003.11.004 CASPubMedWeb of Science®Google Scholar 33 Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824–32. 10.1093/jnci/90.11.824 CASPubMedWeb of Science®Google Scholar 34 Bànkfalvi A, Piffkò J. Prognostic and predictive factors in oral cancer: the role of invasive tumour front. J Oral Pathol Med 2000; 29: 291–8. 10.1034/j.1600-0714.2000.290701.x CASPubMedWeb of Science®Google Scholar 35 Schartinger VL, Kacani L, Ardle J, et al. Pharmacodiagnostic value of the HER family in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 2004; 66: 21–6. 10.1159/000077229 CASPubMedWeb of Science®Google Scholar 36 Laimer K, Spizzo G, Gasti G, et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analisis. Oral Oncol 2007; 43: 193–8. 10.1016/j.oraloncology.2006.02.009 CASPubMedWeb of Science®Google Scholar 37 Fischer C, Zlobec I, Stöckli E, et al. Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas. Human Pathol 2008; 39: 1527–34. 10.1016/j.humpath.2008.03.001 CASPubMedWeb of Science®Google Scholar 38 Monteiro LS, Bento MJ, Palmeira C, Lopes C. Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours. J Oral Pathol Med 2009; 38: 508–13. 10.1111/j.1600-0714.2009.00770.x CASPubMedWeb of Science®Google Scholar 39 Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F. Recent advances in the treatment of salivary gland cancers: emphasis on molecular target therapy. Oral Oncol 2007; 43: 729–34. 10.1016/j.oraloncology.2006.12.012 CASPubMedWeb of Science®Google Scholar 40 Maeda H, Tominaga K, Iwanaga K, et al. Targeted drug delivery system for oral cancer therapy using sonoporation. J Oral Pathol Med 2009; 38: 572–9. 10.1111/j.1600-0714.2009.00759.x CASPubMedWeb of Science®Google Scholar 41 Farshadpour F, Hordijk GJ, Koole R, Slootweg PJ. Head and neck squamous cell carcinoma in non-smoking and non-drinking patients with multiple tumors: etiologic significance of p53 and Ki-67 in non-tumorous epithelium. J Oral Pathol Med 2008; 37: 549–54. 10.1111/j.1600-0714.2008.00657.x CASPubMedWeb of Science®Google Scholar 42 Saarilahti K, Kajanti M, Kouri M, Aaltonen LM, Franssila K, Joensuu H. Cyclin A and Ki-67 expression as predictors for locoregional recurrence and outcome in laryngeal cancer patients treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 986–95. 10.1016/S0360-3016(03)00736-3 CASPubMedWeb of Science®Google Scholar 43 Vicente JC, Zapatero AH, Fresno MF, Arranz JSL. Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the oral cavity: clinicopathological and prognostic significance. Oral Oncol 2002; 38: 301–8. 10.1016/S1368-8375(01)00060-4 PubMedWeb of Science®Google Scholar 44 Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM. Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med 2008; 37: 309–18. 10.1111/j.1600-0714.2007.00631.x CASPubMedWeb of Science®Google Scholar Citing Literature Volume39, Issue7August 2010Pages 571-578 ReferencesRelatedInformation